Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery

被引：0
作者：
Susanne Doblecki-Lewis
Stephanie Cohen
Albert Liu
机构：
[1] University of Miami Miller School of Medicine,Division of Infectious Diseases
[2] San Francisco Department of Health,Population Health Division
[3] San Francisco Department of Health,Bridge HIV
[4] University of California,Division of Infectious Diseases
来源：
Current Treatment Options in Infectious Diseases | 2015年 / 7卷 / 2期
关键词：
HIV prevention; Pre-exposure prophylaxis; Antiretrovirals;
D O I：
10.1007/s40506-015-0046-4
中图分类号：
学科分类号：
摘要：
Pre-exposure prophylaxis (PrEP) is an effective and evidence-based HIV prevention option and is recommended for individuals with substantial risk for HIV infection [1]. Randomized controlled trials have demonstrated that daily oral PrEP dramatically reduces the risk of HIV infection when it is taken as directed. Concerns regarding widespread emergence of antiretroviral resistance attributable to PrEP and behavioral disinhibition have to date not been observed in clinical trials and open-label demonstration projects. PrEP has great potential as part of an HIV risk reduction strategy, and barriers to wider implementation including community education, prescriber availability, and elimination of financial barriers should be aggressively pursued. Adherence is critical to PrEP efficacy and has varied across study populations; developing and refining ways of measuring and supporting adherence is essential to the success of PrEP. Evaluation of long-acting medications and alternative formulations for PrEP is underway and may lead to the wider implementation and impact of PrEP.
引用
收藏
页码：101 / 112
页数：11
相关论文
共 69 条
[1]  
Baeten JM(2012)Antiretroviral prophylaxis for HIV prevention in heterosexual men and women N Engl J Med 367 399-410
[2]  
Choopanya K(2013)Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 381 2083-90
[3]  
Grant RM(2010)Preexposure chemoprophylaxis for HIV prevention in men who have sex with men N Engl J Med 363 2587-99
[4]  
Thigpen MC(2012)Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana N Engl J Med 367 423-34
[5]  
Tsai CC(1995)Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine Science 270 1197-9
[6]  
Garcia-Lerma JG(2008)Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir PLoS Med 5 e28-65
[7]  
Parikh UM(2009)Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine J Virol 83 10358-11
[8]  
Garcia-Lerma JG(2010)Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges Sci Transl Med 2 14ra4-64
[9]  
Subbarao S(2006)Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial J Infect Dis 194 904-73
[10]  
Baeten JM(2014)The nephrotoxic effects of HAART Lancet Infect Dis 14 1055-87
1234567